None listed
Conditions
Interventions
Medical Device : The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol wa
Sponsors
Yeongnam University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects were diagnosed with MDD according to the DSM-IV-TR criteria for MDD, and had especially treatment-resistant MDD. We defined TRD as the failure to achieve remission with remaining persistent depressive symptoms (Hamilton Rating Scale for Depression [HAM-D] score ?14) despite adequate antidepressant therapy (2 or more antidepressant trials involving effective doses and sufficient duration to produce a robust therapeutic effect [e.g., 12 weeks]).
Exclusion criteria
Exclusion criteria: Patients with psychosis, bipolar disorder, brain injury, clinically diagnosed neurological disorder, convulsive disorder, or pregnancy were excluded from participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Rating Scale for Depression [HAM-D];European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D) | — |
Secondary
| Measure | Time frame |
|---|---|
| Beck Depression Inventory- II (BDI-II);Sheehan Disability Scale (SDS);Clinical Global Impression-Severity (CGI-S);serum brain-derived neurotrophic factor (BDNF) level;adverse events | — |
Countries
Korea, Republic of
Contacts
Public ContactEun-Jin Cheon
Yeongnam University Medical Center
Outcome results
None listed